Eli Lilly's third-quarter report is the kind of result that makes skeptics pause. Revenue beat estimates, the company raised its full-year sales outlook to between $91 billion and $92 billion, up from $85 billion to $87 billion, and shares rose about 7% on Thursday. Demand for Zepbound and Mounjaro remains the engine. Mounjaro's worldwide revenue rose 65% to $10.72 billion, beating the $10.10 billion analysts expected, and Zepbound posted $5.35 billion, up 49% from a year earlier.

The more interesting number is the one that missed. Foundayo, the company's GLP-1 obesity pill launched in the U.S. in April, brought in $184 million in the quarter, below analyst forecasts of around $229 million. Lilly's own data offers some encouragement: according to CFO Lucas Montarces, total U.S. prescriptions and new patients for Foundayo doubled from the prior quarter, and about 4 in 10 patients starting an oral obesity medicine choose it. Still, the pill is competing head-to-head with a rival oral drug from Novo that launched in January, and a launch that doubles from a small base can still fall short of Wall Street's hopes.

Lilly's market position is the real story. The company reported a 63% share of the U.S. obesity and diabetes drug market in the third quarter, against Novo's 36.6%, and Montarces said 7 out of 10 U.S. prescriptions for injectable obesity and diabetes drugs went to a Lilly medicine. CEO Dave Ricks told CNBC that he estimates 3% to 10% of eligible patients access obesity care in the U.S., and that the "room for expansion here of this market is dramatic." That is a bold claim from the company best positioned to profit from it, and investors should weigh it accordingly.

The pricing picture deserves equal attention. U.S. realized prices fell 7%, driven mainly by Zepbound, after a drug pricing deal with the Trump administration last year. Volume growth of 41% in the U.S. has more than offset that decline, but it means Lilly is betting on sustained prescription growth to protect margins. Lilly also credited Medicare's temporary pilot covering GLP-1s for weight loss, which began in July, for expanded access. Whether that program keeps delivering uptake will matter more to the company's trajectory than any single quarter.

My conclusion is that Lilly should keep its lead, but the next test is Foundayo and pricing, not headline demand. Regulators, payers and investors should watch whether the oral launch closes its gap with forecasts and whether volume can keep outrunning price cuts. Ricks's market-expansion thesis is plausible, yet it rests on patients gaining coverage and on the company continuing to convert profits into deals such as its agreement to buy Merida Biosciences. Those are the points to press as the year closes.